Zobrazeno 1 - 8
of 8
pro vyhledávání: '"NIAID H"'
Publikováno v:
Retrovirology, Vol 9, Iss Suppl 2, p P133 (2012)
Externí odkaz:
https://doaj.org/article/cfd4564c1c7042f4a70ad2f0d3a893dc
Autor:
Kelly E. Seaton, Aaron Deal, Xue Han, Shuying S. Li, Ashley Clayton, Jack Heptinstall, Ann Duerr, Mary A. Allen, Xiaoying Shen, Sheetal Sawant, Nicole L. Yates, Paul Spearman, Gavin Churchyard, Paul A. Goepfert, Janine Maenza, Glenda Gray, Giuseppe Pantaleo, Laura Polakowski, Harriet L. Robinson, Shannon Grant, April K. Randhawa, Ying Huang, Cecilia Morgan, Nicole Grunenberg, Shelly Karuna, Peter B. Gilbert, M. Juliana McElrath, Yunda Huang, Georgia D. Tomaras, NIAID HIV Vaccine Trials Network (HVTN) 076, 088, 086, 096, 097, 205 Study Teams
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
Abstract We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone
Externí odkaz:
https://doaj.org/article/2f212191b8044471a09de9b169fd03d0
Autor:
Zoe Moodie, Stephen R Walsh, Fatima Laher, Lucas Maganga, Michael E Herce, Sarita Naidoo, Mina C Hosseinipour, Craig Innes, Linda-Gail Bekker, Nicole Grunenberg, Philipp Mann, Chenchen Yu, Allan C deCamp, Maurine D Miner, Nicole L Yates, Jack Heptinstall, Nonhlanhla N Mkhize, One Dintwe, Nicole Frahm, Kristen W Cohen, Mary Allen, Julia Hutter, Ralf Wagner, Giuseppe Pantaleo, M Juliana McElrath, Georgia D Tomaras, Lynn Morris, David C Montefiori, Erica Andersen-Nissen, Glenda E Gray, Peter B Gilbert, James G Kublin, NIAID HVTN 100 and HVTN 111 trial teams
Publikováno v:
PLoS Medicine, Vol 17, Iss 5, p e1003117 (2020)
BackgroundDNA plasmids promise a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines. We evaluated DNA plasmid versus canarypox virus (ALVAC) primes in 2 randomized, double-blind, placebo-controlled trials in southern Africa with ha
Externí odkaz:
https://doaj.org/article/7c285a3459774f30806f3e5507798d93
Autor:
Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, Gregory J Wilson, Mary A Allen, Hong Van N Tieu, Ian Frank, Magdalena E Sobieszczyk, Kristen W Cohen, Brittany Sanchez, Theresa E Latham, David K Clarke, Michael A Egan, John H Eldridge, Drew Hannaman, Rong Xu, Ayuko Ota-Setlik, M Juliana McElrath, Christine Mhorag Hay, NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0202753 (2018)
BACKGROUND:The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study was to test the safe
Externí odkaz:
https://doaj.org/article/799ab45103694bff91a425fb6ec10484
Autor:
Spyros A Kalams, Scott Parker, Xia Jin, Marnie Elizaga, Barbara Metch, Maggie Wang, John Hural, Michael Lubeck, John Eldridge, Massimo Cardinali, William A Blattner, Magda Sobieszczyk, Vinai Suriyanon, Artur Kalichman, David B Weiner, Lindsey R Baden, NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS ONE, Vol 7, Iss 1, p e29231 (2012)
DNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced immunity. DNA plasmid cytokine adjuvants have been shown to augment immune responses in small animals and in macaques.We performed two first in h
Externí odkaz:
https://doaj.org/article/25ca3b4fc77248efaf40bc1ecfcfc20f
Autor:
Gavin J Churchyard, Cecilia Morgan, Elizabeth Adams, John Hural, Barney S Graham, Zoe Moodie, Doug Grove, Glenda Gray, Linda-Gail Bekker, M Juliana McElrath, Georgia D Tomaras, Paul Goepfert, Spyros Kalams, Lindsey R Baden, Michelle Lally, Raphael Dolin, William Blattner, Artur Kalichman, J Peter Figueroa, Jean Pape, Mauro Schechter, Olivier Defawe, Stephen C De Rosa, David C Montefiori, Gary J Nabel, Lawrence Corey, Michael C Keefer, NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e21225 (2011)
The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB, envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated in HIV-seronegative part
Externí odkaz:
https://doaj.org/article/5dc1c0316ec6406fbd78dd8ab1a777f9
Autor:
Beryl A Koblin, Martin Casapia, Cecilia Morgan, Li Qin, Zhixue Maggie Wang, Olivier D Defawe, Lindsey Baden, Paul Goepfert, Georgia D Tomaras, David C Montefiori, M Juliana McElrath, Lilian Saavedra, Chuen-Yen Lau, Barney S Graham, NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24517 (2011)
In the development of HIV vaccines, improving immunogenicity while maintaining safety is critical. Route of administration can be an important factor.This multicenter, open-label, randomized trial, HVTN 069, compared routes of administration on safet
Externí odkaz:
https://doaj.org/article/8c2643b03e8444629b99a65e764f618e
Autor:
Laurence Peiperl, Cecilia Morgan, Zoe Moodie, Hongli Li, Nina Russell, Barney S Graham, Georgia D Tomaras, Stephen C De Rosa, M Juliana McElrath, NIAID HIV Vaccine Trials Network
Publikováno v:
PLoS ONE, Vol 5, Iss 10, p e13579 (2010)
Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector
Externí odkaz:
https://doaj.org/article/796823acb3a246abb29157e03fbae45a